Anti IL-36R antibodies
US-9023995-B2 · May 5, 2015 · US
Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
US2019284285A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019284285-A1 |
| Application number | US-201916296825-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 8, 2019 |
| Priority date | Mar 14, 2018 |
| Publication date | Sep 19, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the treatment of or alleviation of signs and symptoms of an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-IL36R antibodies.
First claim
Opening claim text (preview).
1 - 38 . (canceled) 39 . A method of treating generalized pustular psoriasis (GPP) in a patient, said method comprising administering or having administered to the patient a therapeutically effective amount of an anti-IL-36R antibody, wherein the anti-IL-36R antibody is administered in one or more intravenous doses comprising 210 mg, 300 mg, 350 mg, 450 mg, 600 mg, 700 mg, 750 mg, 800 mg, 850 mg or 900 mg of the anti-IL-36R antibody, wherein the anti-IL-36R antibody comprises: (i) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87; or (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or (iii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or (iv) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87; or (v) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or (vi) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or (vii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or (viii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101; or (ix) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or (x) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101. 40 . The method of claim 39 , wherein the anti-IL-36R antibody is administered in one intravenous dose of 700 mg. 41 . The method of claim 39 , wherein the anti-IL-36R antibody is administered in one intravenous dose of 750 mg. 42 . The method of claim 39 , wherein the anti-IL-36R antibody is administered in one intravenous dose of 800 mg. 43 . The method of claim 39 , wherein the anti-IL-36R antibody is administered in one intravenous dose of 850 mg. 44 . The method of claim 39 , wherein the anti-IL-36R antibody is administered in one intravenous dose of 900 mg. 45 . The method of claim 39 , wherein 1, 2 or 3 intravenous doses is/are administered. 46 . The method of claim 45 , wherein 2 or 3 intravenous doses are administered at 4 to 12 weeks intervals. 47 . A method of treating generalized pustular psoriasis (GPP) in a patient, said method comprising administering or having administered to the patient a therapeutically effective amount of an anti-IL-36R antibody, wherein the anti-IL-36R antibody is administered in one intravenous dose of about 10 mg per kilogram of body weight of the patient, wherein the anti-IL-36R antibody comprises: (i) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87; or (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or (iii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or (iv) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87; or (v) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88; or (vi) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or (vii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or (viii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101; or (ix) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100; or (x) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:101.
Assignees
Inventors
Classifications
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
comprising antibodies · CPC title
- C07K16/2866Primary
against receptors for cytokines, lymphokines, interferons · CPC title
characterised by the route of administration · CPC title
Antipsoriatics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019284285A1 cover?
- The present invention relates to the treatment of or alleviation of signs and symptoms of an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-IL36R antibodies.
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Sep 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).